I appreciate all of your interest in the contact lens solution we are working on. As a courtesy, I want to provide all those interested in these lenses with the most accurate and scientifically validated information as possible. With that being said, there is simply some things I am unable to delve into at this time since we are in the development stage. I see two main problems with the color vision aids currently on the market, firstly, the retail prices are expensive and the overall value comes into question, for example the Colormax lens can cost thousands and make little change to a persons ability to discriminate colors. Secondly, how the lenses are prescribed, because color vision deficiency is highly variable it is a challenge to prescribe the correct "level" of tint. The current testing methods, for ex. the Ishihara Test was never designed to gauge type or severity. I am baffled with how a tinted lens can be accurately prescribed with such a screener. It leads me to believe that it is a one size fits all approach.
We are working on coupling a tinted lens prescription within the treatment plan portion of the results from our genetic test. Since our genetic test can determine the exact type of deficiency and the precise extent/severity, we are confident, by using the spectral peaks of the photoreceptors, that we can accurately prescribe the correct level of tint for the maximum benefit. The other part is to offer the solution at a reasonable price. I would be interested to know what you folks would pay for an accurate lens solution that works. My target would be around $700 including physician compensation. A bi-product of this prescription method would be that virtually anyone around the world could order the genetic test and have a lens prescription that they could order by mail; versus trying to track down a non-existent eye doctor in their country to help them. I would also appreciate your view on that angle as well.
Ultimately, everyone who has a color vision deficiency needs and deserves to have accurate information about the nature of their color vision. Unfortunately, even highly trained optometrists and ophthalmologists are unable to objectively discuss color vision deficiency with their patients because of a lack of a proper diagnosis. A growing number of everyday activities and professions rely on color vision. Presently, the most widely used test of color blindness is Ishihara's Test. Japanese ophthalmologist, Dr. Shinobu Ishiáhaára, introduced this in 1917. It is long out dated and does not reflect any of our current knowledge of the nature of colorblindness. It fails to test for one of the major forms of colorblindness (blue-yellow) completely. It was not designed to distinguish among different levels of severity of color vision defect. People with the minimal and extreme forms receive the same diagnosis with the Ishihara. Moreover, people, especially children, can be diagnosed as being colorblind when they are not. The use of Ishihara's test has, in many ways, done more harm than good. Our genetic test represents the natural progression of color vision testing. Over the years, we have received emails, calls and letters from thousands of frustrated colorblind people. The outcry from patients together with feedback from practicing clinicians who have indicated that a genetic test will change everything for them and that they would use it, if it was available, motivated us to develop the test as a commercial product.
Ultimately, a genetic test for colorblindness will be the standard of care administered to all patients. From a clinical point of view, it is just as important to know a patient has normal color vision as it is to know the details of a color vision defect. This is because many vision problems have a color vision abnormality as an early symptom. In order to diagnose and treat such conditions, it is critical to know the patients genetic color vision status. Thus, it is important to understand that potential consumers of the test are not just the world's colorblind people--it is everyone.
As I explained before, our ultimate goal is to have a safe cure available to humans. This process will likely take years, but we think that having a accurate and effective bridge contact lens solution available now would be neat. Also, we now know that the implications for colorblindness on a person's life are dramatically dependent on the type and severity, which can be determined accurately with a genetic test. I encourage all interested in learning more to review our sample diagnosis report at :
http://www.genevolve.com/genetic-test.html
We welcome any feedback especially on the treatment plan portion of the sample report.
-Matt